Adaptive Biotechnologies (ADPT) Total Non-Current Liabilities (2019 - 2026)

Adaptive Biotechnologies (ADPT) has 7 years of Total Non-Current Liabilities data on file, last reported at $281.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 12.14% year-over-year to $281.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.7 million (down 12.14% YoY) and the FY2025 annual result came in at $287.7 million, down 14.59% from the prior year.
• Total Non-Current Liabilities eased to $281.7 million in Q1 2026 per ADPT's latest filing, from $287.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $343.4 million in Q2 2024, with the low at $240.4 million in Q2 2023.
• Average Total Non-Current Liabilities over 5 years is $294.0 million, with a median of $287.0 million recorded in 2025.
• Year-over-year, Total Non-Current Liabilities jumped 42.85% in 2024 and dropped 14.59% in 2025.
• Adaptive Biotechnologies' Total Non-Current Liabilities stood at $267.2 million in 2022, then retreated by 10.01% to $240.4 million in 2023, then soared by 40.13% to $336.9 million in 2024, then declined by 14.59% to $287.7 million in 2025, then declined by 2.1% to $281.7 million in 2026.
• Business Quant data shows ADPT's Total Non-Current Liabilities at $281.7 million in Q1 2026, $287.7 million in Q4 2025, and $286.3 million in Q3 2025.